SG11201907867TA - Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine - Google Patents
Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccineInfo
- Publication number
- SG11201907867TA SG11201907867TA SG11201907867TA SG11201907867TA SG11201907867TA SG 11201907867T A SG11201907867T A SG 11201907867TA SG 11201907867T A SG11201907867T A SG 11201907867TA SG 11201907867T A SG11201907867T A SG 11201907867TA SG 11201907867T A SG11201907867T A SG 11201907867TA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- bristol
- rule
- ctla
- antibodies
- Prior art date
Links
- 230000028993 immune response Effects 0.000 title abstract 3
- 229960005486 vaccine Drugs 0.000 title abstract 3
- 229940045513 CTLA4 antagonist Drugs 0.000 abstract 3
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 abstract 2
- 240000005020 Acaciella glauca Species 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 229960005386 ipilimumab Drugs 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
- 235000003499 redwood Nutrition 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/21—Retroviridae, e.g. equine infectious anemia virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/524—CH2 domain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Communicable Diseases (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 07 September 2018 (07.09.2018) WIPO I PCT omit VIII °nolo omioollm 1o11 oo1 IIII mom oimIE (10) International Publication Number WO 2018/160536 Al W O 20 18/1605 36 Al (51) International Patent Classification: C07K 16/28 (2006.01) A61K 39/395 (2006.01) A61K 39/00 (2006.01) A61K 39/21 (2006.01) (21) International Application Number: PCT/US2018/019868 (22) International Filing Date: 27 February 2018 (27.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/464,738 28 February 2017 (28.02.2017) US 62/468,527 08 March 2017 (08.03.2017) US (71) Applicant: BRISTOL-MYERS SQUIBB COMPANY [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (72) Inventors: LOFFREDO, John T.; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). LEWIS, Katherine E.; 19719 53rd Avenue NE, Lake Forest Park, Washing- ton 98155 (US). GRAZIANO, Robert F.; c/o Bristol-My- ers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). KORMAN, Alan J.; c/ o Bristol-Myers Squibb Company, 700 Bay Road, Redwood City, California 94063 (US). (74) Agent: BELLOMY, Gregory R. et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) of inventorship (Rule 4.17(iv)) Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: USE OF ANTI-CTLA-4 ANTIBODIES WITH ENHANCED ADCC TO ENHANCE IMMUNE RESPONSE TO A VAC- CINE (57) : The present invention provides methods of enhancing immune response to a vaccine using variant forms of anti-CTLA-4 antibodies having enhanced ADCC activity. Variant anti-CTLA-4 antibodies for use in the present invention include nonfucosylated ipilimumab.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762464738P | 2017-02-28 | 2017-02-28 | |
US201762468527P | 2017-03-08 | 2017-03-08 | |
PCT/US2018/019868 WO2018160536A1 (en) | 2017-02-28 | 2018-02-27 | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201907867TA true SG11201907867TA (en) | 2019-09-27 |
Family
ID=61622729
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201907867TA SG11201907867TA (en) | 2017-02-28 | 2018-02-27 | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine |
Country Status (12)
Country | Link |
---|---|
US (2) | US20190382490A1 (en) |
EP (1) | EP3596122A1 (en) |
JP (2) | JP2020509037A (en) |
KR (1) | KR20190124256A (en) |
CN (2) | CN110366565A (en) |
AU (1) | AU2018227428A1 (en) |
BR (1) | BR112019017695A2 (en) |
CA (1) | CA3054928A1 (en) |
IL (1) | IL268881A (en) |
MX (1) | MX2019009660A (en) |
SG (1) | SG11201907867TA (en) |
WO (1) | WO2018160536A1 (en) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MX2019006340A (en) | 2016-12-07 | 2019-11-07 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof. |
CA3060618A1 (en) | 2017-05-19 | 2018-11-22 | Wuxi Biologics (Shanghai) Co. Ltd. | Novel monoclonal antibodies to cytotoxic t-lymphocyte-associated protein 4 (ctla-4) |
TW202003565A (en) | 2018-03-23 | 2020-01-16 | 美商必治妥美雅史谷比公司 | Antibodies against MICA and/or MICB and uses thereof |
CN113614109A (en) | 2018-12-21 | 2021-11-05 | Ose免疫疗法公司 | Bifunctional anti-PD-1/IL-7 molecules |
WO2020165374A1 (en) | 2019-02-14 | 2020-08-20 | Ose Immunotherapeutics | Bifunctional molecule comprising il-15ra |
CN110218707B (en) * | 2019-05-29 | 2021-10-22 | 上海市公共卫生临床中心 | Novel oncolytic virus and preparation method and application thereof |
TW202136287A (en) | 2019-12-17 | 2021-10-01 | 法商Ose免疫治療公司 | Bifunctional molecules comprising an il-7 variant |
US20230203164A1 (en) * | 2019-12-25 | 2023-06-29 | Bio-Thera Solutions, Ltd. | Anti-ctla-4 monoclonal antibody, preparation method therefor, and application thereof |
EP4208200A2 (en) | 2020-09-02 | 2023-07-12 | Genmab A/S | Antibody therapy |
KR20230097156A (en) | 2020-11-06 | 2023-06-30 | 브리스톨-마이어스 스큅 컴퍼니 | Dosing and Administration of Non-fucosylated Anti-CTLA-4 Antibodies as Monotherapy |
WO2022112198A1 (en) | 2020-11-24 | 2022-06-02 | Worldwide Innovative Network | Method to select the optimal immune checkpoint therapies |
CN116583300A (en) * | 2020-12-03 | 2023-08-11 | 江苏恒瑞医药股份有限公司 | Multispecific antigen-binding proteins |
WO2022214652A1 (en) | 2021-04-09 | 2022-10-13 | Ose Immunotherapeutics | Scaffold for bifunctioanl molecules comprising pd-1 or cd28 and sirp binding domains |
IL307419A (en) | 2021-04-09 | 2023-12-01 | Ose Immunotherapeutics | New scaffold for bifunctional molecules with improved properties |
WO2024003360A1 (en) | 2022-07-01 | 2024-01-04 | Institut Curie | Biomarkers and uses thereof for the treatment of neuroblastoma |
WO2024028386A1 (en) | 2022-08-02 | 2024-02-08 | Ose Immunotherapeutics | Multifunctional molecule directed against cd28 |
CN117618555A (en) * | 2022-08-31 | 2024-03-01 | 百奥泰生物制药股份有限公司 | Use of anti-TIGIT antibodies in combination with anti-CTLA-4 antibodies for the treatment of tumors |
Family Cites Families (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5851795A (en) | 1991-06-27 | 1998-12-22 | Bristol-Myers Squibb Company | Soluble CTLA4 molecules and uses thereof |
AU661854B2 (en) | 1991-06-27 | 1995-08-10 | Bristol-Myers Squibb Company | CTL4A receptor, fusion proteins containing it and uses thereof |
US5811097A (en) | 1995-07-25 | 1998-09-22 | The Regents Of The University Of California | Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling |
AU3657899A (en) | 1998-04-20 | 1999-11-08 | James E. Bailey | Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity |
JP5341287B2 (en) | 1998-12-03 | 2013-11-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Stimulation of T cells against self antigens using CTLA-4 blockers |
US6682736B1 (en) | 1998-12-23 | 2004-01-27 | Abgenix, Inc. | Human monoclonal antibodies to CTLA-4 |
US7109003B2 (en) | 1998-12-23 | 2006-09-19 | Abgenix, Inc. | Methods for expressing and recovering human monoclonal antibodies to CTLA-4 |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
EP2829609A1 (en) | 1999-08-24 | 2015-01-28 | E. R. Squibb & Sons, L.L.C. | Human CTLA-4 antibodies and their uses |
US7605238B2 (en) | 1999-08-24 | 2009-10-20 | Medarex, Inc. | Human CTLA-4 antibodies and their uses |
JP3523245B1 (en) | 2000-11-30 | 2004-04-26 | メダレックス,インコーポレーテッド | Transgenic chromosome-introduced rodents for the production of human antibodies |
ES2326964T3 (en) | 2001-10-25 | 2009-10-22 | Genentech, Inc. | GLICOPROTEIN COMPOSITIONS. |
US20040002587A1 (en) | 2002-02-20 | 2004-01-01 | Watkins Jeffry D. | Fc region variants |
US20040110704A1 (en) | 2002-04-09 | 2004-06-10 | Kyowa Hakko Kogyo Co., Ltd. | Cells of which genome is modified |
WO2003086459A1 (en) | 2002-04-12 | 2003-10-23 | Medarex, Inc. | Methods of treatement using ctla-4 antibodies |
US7465446B2 (en) | 2003-05-30 | 2008-12-16 | Medarex, Inc. | Surrogate therapeutic endpoint for anti-CTLA4-based immunotherapy of disease |
EP2053062A1 (en) | 2004-03-24 | 2009-04-29 | Xencor, Inc. | Immunoglobin variants outside the Fc region |
EA012464B1 (en) | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Antibody against cd20 and use thereof |
MX2007009935A (en) | 2005-02-18 | 2007-10-10 | Medarex Inc | Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues. |
LT2439273T (en) | 2005-05-09 | 2019-05-10 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
US20090117132A1 (en) * | 2005-07-07 | 2009-05-07 | Pfizer, Inc. | Anti-Ctla-4 Antibody and Cpg-Motif-Containing Synthetic Oligodeoxynucleotide Combination Therapy for Cancer Treatment |
JP2009514977A (en) | 2005-11-08 | 2009-04-09 | メダレックス インコーポレーティッド | TNF-α blocking agent treatment method for enteritis associated with treatment with immunostimulatory therapeutic antibody |
AU2006321593B2 (en) | 2005-12-07 | 2012-10-04 | E. R. Squibb & Sons, L.L.C. | CTLA-4 antibody dosage escalation regimens |
US20090175886A1 (en) | 2006-01-17 | 2009-07-09 | Medarex, Inc. | Monoclonal antibodies against cd30 lacking in fucosyl and xylosyl residues |
US8652466B2 (en) | 2006-12-08 | 2014-02-18 | Macrogenics, Inc. | Methods for the treatment of disease using immunoglobulins having Fc regions with altered affinities for FcγRactivating and FcγRinhibiting |
WO2008109075A2 (en) | 2007-03-05 | 2008-09-12 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to ctla-4 antagonists |
AU2009204194A1 (en) | 2008-01-08 | 2009-07-16 | Bristol-Myers Squibb Company | Combination of anti-CTLA4 antibody with tubulin modulating agents for the treatment of proliferative diseases |
WO2009100140A1 (en) | 2008-02-04 | 2009-08-13 | Medarex, Inc. | Anti-clta-4 antibodies with reduced blocking of binding of ctla-4 to b7 and uses thereof |
ES2458541T3 (en) | 2008-05-02 | 2014-05-06 | Seattle Genetics, Inc. | Methods and compositions for making antibodies and antibody derivatives with reduced core fucosylation |
US20090311187A1 (en) | 2008-05-29 | 2009-12-17 | Bristol-Myers Squibb Company | Methods for predicting patient response to modulation of the Co-stimulatory pathway |
WO2010014784A2 (en) | 2008-08-01 | 2010-02-04 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
US8475790B2 (en) | 2008-10-06 | 2013-07-02 | Bristol-Myers Squibb Company | Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases |
GB0903325D0 (en) * | 2009-02-26 | 2009-04-08 | Univ Aberdeen | Antibody molecules |
EP2456790A1 (en) | 2009-07-20 | 2012-05-30 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with diverse therapeutic regimens for the synergistic treatment of proliferative diseases |
WO2011035884A1 (en) | 2009-09-22 | 2011-03-31 | Volker Sandig | Process for producing molecules containing specialized glycan structures |
WO2011146382A1 (en) | 2010-05-17 | 2011-11-24 | Bristol-Myers Squibb Company | Improved immunotherapeutic dosing regimens and combinations thereof |
US20130156768A1 (en) | 2010-08-26 | 2013-06-20 | Bristol-Myers Squibb Company | Combination of anti-ctla4 antibody with braf inhibitors for the synergistic treatment of proliferative diseases |
GB201103955D0 (en) * | 2011-03-09 | 2011-04-20 | Antitope Ltd | Antibodies |
HUE033008T2 (en) | 2011-04-13 | 2017-11-28 | Bristol Myers Squibb Co | Fc fusion proteins comprising novel linkers or arrangements |
WO2013138702A2 (en) | 2012-03-15 | 2013-09-19 | Bristol-Myers Squibb Company | Methods for predicting gastrointestinal immune-related adverse events (gi-irae) in patients treated with modulation of the co-stimulatory pathway |
US20150079100A1 (en) | 2012-03-23 | 2015-03-19 | Bristol-Myers Squibb Company | Methods of treatments using ctla-4 antibodies |
WO2013169971A1 (en) | 2012-05-10 | 2013-11-14 | Bristol-Myers Squibb Company | Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients |
RS58528B1 (en) * | 2012-12-03 | 2019-04-30 | Bristol Myers Squibb Co | Enhancing anti-cancer activity of immunomodulatory fc fusion proteins |
BR112016026299A2 (en) * | 2014-05-13 | 2018-02-20 | Chugai Seiyaku Kabushiki Kaisha | The T-lymph cell redirection antigen joint molecule to the cell which has an immunosuppressive function |
EP3256156A1 (en) * | 2015-02-13 | 2017-12-20 | Transgene SA | Immunotherapeutic vaccine and antibody combination therapy |
SG10201913500TA (en) * | 2015-05-29 | 2020-03-30 | Agenus Inc | Anti-ctla-4 antibodies and methods of use thereof |
-
2018
- 2018-02-27 WO PCT/US2018/019868 patent/WO2018160536A1/en unknown
- 2018-02-27 KR KR1020197028077A patent/KR20190124256A/en not_active Application Discontinuation
- 2018-02-27 AU AU2018227428A patent/AU2018227428A1/en active Pending
- 2018-02-27 CA CA3054928A patent/CA3054928A1/en active Pending
- 2018-02-27 CN CN201880014676.2A patent/CN110366565A/en active Pending
- 2018-02-27 US US16/488,118 patent/US20190382490A1/en not_active Abandoned
- 2018-02-27 CN CN202211603585.7A patent/CN116440257A/en active Pending
- 2018-02-27 MX MX2019009660A patent/MX2019009660A/en unknown
- 2018-02-27 SG SG11201907867TA patent/SG11201907867TA/en unknown
- 2018-02-27 BR BR112019017695A patent/BR112019017695A2/en unknown
- 2018-02-27 EP EP18710641.4A patent/EP3596122A1/en not_active Withdrawn
- 2018-02-27 JP JP2019547378A patent/JP2020509037A/en active Pending
-
2019
- 2019-08-23 IL IL26888119A patent/IL268881A/en unknown
-
2022
- 2022-01-13 US US17/575,498 patent/US20220127363A1/en active Pending
-
2023
- 2023-02-03 JP JP2023015068A patent/JP2023055885A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN116440257A (en) | 2023-07-18 |
BR112019017695A2 (en) | 2020-04-07 |
KR20190124256A (en) | 2019-11-04 |
MX2019009660A (en) | 2019-10-02 |
US20190382490A1 (en) | 2019-12-19 |
JP2023055885A (en) | 2023-04-18 |
CN110366565A (en) | 2019-10-22 |
AU2018227428A1 (en) | 2019-10-17 |
IL268881A (en) | 2019-10-31 |
EP3596122A1 (en) | 2020-01-22 |
JP2020509037A (en) | 2020-03-26 |
WO2018160536A1 (en) | 2018-09-07 |
CA3054928A1 (en) | 2018-09-07 |
US20220127363A1 (en) | 2022-04-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201905699XA (en) | Anti-icos agonist antibodies and uses thereof | |
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201809336QA (en) | Anti-pd-l1 antibodies | |
SG11201811490XA (en) | Cd3 binding antibodies | |
SG11201903359RA (en) | Bispecific antibody against bcma and cd3 and an immunological drug for combined use in treating multiple myeloma | |
SG11201910134SA (en) | Stable formulations of anti-ctla4 antibodies alone and in combination with programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201903882VA (en) | Il-2 variants for the treatment of autoimmune diseases | |
SG11201910182RA (en) | Stable formulations of programmed death receptor 1 (pd-1) antibodies and methods of use thereof | |
SG11201909646TA (en) | Trem2 antigen binding proteins and uses thereof | |
SG11201811003PA (en) | Anti-pd-l1 antibodies and uses thereof | |
SG11201805870YA (en) | Bispecific t cell engaging antibody constructs | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201805770UA (en) | BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs | |
SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
SG11201407580YA (en) | Composition comprising two antibodies engineered to have reduced and increased effector function | |
SG11201408780XA (en) | Optimization of antibodies that bind lymphocyte activation gene-3 (lag-3), and uses thereof | |
SG11201908326YA (en) | Methods of treating neurodegenerative diseases | |
SG11201903693QA (en) | Polypeptide variants and uses thereof | |
SG11201408646VA (en) | Dimeric protein with triple mutations | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201806496SA (en) | Antigen binding proteins that bind pd-l1 | |
SG11201806121PA (en) | Ror2 antibody compositions and related methods | |
SG11201810927QA (en) | Pd-l1-specific antibodies and methods of using the same | |
SG11201810429UA (en) | Anti-cd19 antibody formulations |